<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Assignment of the correct molecular diagnosis in <z:mp ids='MP_0002055'>diabetes</z:mp> is necessary for informed decisions regarding treatment and prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>Better clinical markers would facilitate discrimination and prioritization for genetic testing between <z:mp ids='MP_0002055'>diabetes</z:mp> subtypes </plain></SENT>
<SENT sid="2" pm="."><plain>Serum 1,5 anhydroglucitol (1,5AG) levels were reported to differentiate <z:hpo ids='HP_0004904'>maturity-onset diabetes of the young</z:hpo> due to HNF1A mutations (HNF1A-MODY) from type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, but this requires further validation </plain></SENT>
<SENT sid="3" pm="."><plain>We evaluated serum 1,5AG in a range of <z:mp ids='MP_0002055'>diabetes</z:mp> subtypes as an adjunct for defining <z:mp ids='MP_0002055'>diabetes</z:mp> etiology </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: 1,5AG was measured in U.K. subjects with: HNF1A-MODY (n = 23), MODY due to glucokinase mutations (GCK-MODY, n = 23), type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 29), latent autoimmune <z:mp ids='MP_0002055'>diabetes</z:mp> in adults (LADA, n = 42), and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 206) </plain></SENT>
<SENT sid="5" pm="."><plain>Receiver operating characteristic curve analysis was performed to assess discriminative accuracy of 1,5AG for <z:mp ids='MP_0002055'>diabetes</z:mp> etiology </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Mean (SD range) 1,5AG levels were: GCK-MODY 13.06 microg/ml (5.74-29.74), HNF1A-MODY 4.23 microg/ml (2.12-8.44), type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> 3.09 microg/ml (1.45-6.57), LADA 3.46 microg/ml (1.42-8.45), and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> 5.43 (2.12-13.23) </plain></SENT>
<SENT sid="7" pm="."><plain>Levels in GCK-MODY were higher than in other groups (P &lt; 10(-4) vs. each group) </plain></SENT>
<SENT sid="8" pm="."><plain>HNF1A-MODY subjects showed no difference in unadjusted 1,5AG levels from type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, and LADA </plain></SENT>
<SENT sid="9" pm="."><plain>Adjusting for A1C revealed a difference between HNF1A-MODY and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (P = 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>The discriminative accuracy of unadjusted 1,5AG levels was 0.79 for GCK-MODY versus type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and 0.86 for GCK-MODY versus HNF1A-MODY but was only 0.60 for HNF1A-MODY versus type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: In our dataset, serum 1,5AG performed well in discriminating GCK-MODY from other <z:mp ids='MP_0002055'>diabetes</z:mp> subtypes, particularly HNF1A-MODY </plain></SENT>
<SENT sid="12" pm="."><plain>Measurement of 1,5AG levels could inform decisions regarding MODY diagnostic testing </plain></SENT>
</text></document>